Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)
Post# of 721
(Total Views: 137)
Posted On: 11/08/2017 6:08:56 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Boosts Revenue by Out-Licensing Patented Technology to Third-Party Partners
- High-margin licensing royalties of 5-10% of gross sales of its patented bioscience technology and process are an attractive valuation builder; LXRP sees more licensing opportunities in 2018
- LXRP’s technology is patented in the U.S. and Australia; company has national/regional filings pending in 44 countries
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) generates revenue by out-licensing its patented global technology related to ingestion of edible cannabinoids at a rate of 5-10% of gross sales to its third-party partners. LXRP has also expanded its process of improved and faster inhalation by the body of fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) in pain medications, and even nicotine, a good example of bioabsorption breakthrough technology (http://nnw.fm/GhD5A). LXRP is now positioned to license its technology to tobacco giants and major drug companies, as well as cannabinoid biopharmaceutical companies.
As a result, LXRP sees new business opportunities in 2018. The company is now positioned to out-license — at a high royalty rate — its intellectual property (IP) to biopharmaceutical companies as a partner rather than a competitor, working with other companies, including cannabinoid edible producers, instead of competing with them.
An R&D-driven company, LXRP is disrupting the global industry by specializing in the ingestion of edible forms of cannabinoids. Its technology and process platform offers more rapid forms of delivery and intestinal absorption of orally-taken cannabinoids, vitamins, nicotine and non-steroidal inflammatory drugs. Its patented process not only improves the body’s absorption of edible cannabinoids; it also masks taste, reduces by roughly 75% the time of onset, and increases bio-absorption by 5-10x. The company has secured patents related to its processing technology in the U.S. and Australia, and it has a portfolio of some 19 national/regional patent application filings in some 44 countries (http://nnw.fm/n4NqG).
Primarily a B2B company, LXRP also makes for demonstration purposes branded consumer products under the ViPova™, Lexaria Energy Foods, and TurboCBD™ brands. It recently acquired the remaining 49% of its majority owned Poviva Tea LLC subsidiary (http://nnw.fm/Mow3Z). It now owns 100% ownership interest, reaffirming its commitment to the ViPova product lines, as noted by the company in a recent news release.
Separately, in financial news, LXRP has extended the date of its warrants issued on January 19, 2017, to expire on January 19, 2019. The exercise price and the quantity of the warrants has not changed, it said in a 8K SEC filing. LXRP, in its corporate presentation, said that the next round of capital investment is expected to be in “plant to bloodstream” companies, such as itself.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- High-margin licensing royalties of 5-10% of gross sales of its patented bioscience technology and process are an attractive valuation builder; LXRP sees more licensing opportunities in 2018
- LXRP’s technology is patented in the U.S. and Australia; company has national/regional filings pending in 44 countries
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) generates revenue by out-licensing its patented global technology related to ingestion of edible cannabinoids at a rate of 5-10% of gross sales to its third-party partners. LXRP has also expanded its process of improved and faster inhalation by the body of fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) in pain medications, and even nicotine, a good example of bioabsorption breakthrough technology (http://nnw.fm/GhD5A). LXRP is now positioned to license its technology to tobacco giants and major drug companies, as well as cannabinoid biopharmaceutical companies.
As a result, LXRP sees new business opportunities in 2018. The company is now positioned to out-license — at a high royalty rate — its intellectual property (IP) to biopharmaceutical companies as a partner rather than a competitor, working with other companies, including cannabinoid edible producers, instead of competing with them.
An R&D-driven company, LXRP is disrupting the global industry by specializing in the ingestion of edible forms of cannabinoids. Its technology and process platform offers more rapid forms of delivery and intestinal absorption of orally-taken cannabinoids, vitamins, nicotine and non-steroidal inflammatory drugs. Its patented process not only improves the body’s absorption of edible cannabinoids; it also masks taste, reduces by roughly 75% the time of onset, and increases bio-absorption by 5-10x. The company has secured patents related to its processing technology in the U.S. and Australia, and it has a portfolio of some 19 national/regional patent application filings in some 44 countries (http://nnw.fm/n4NqG).
Primarily a B2B company, LXRP also makes for demonstration purposes branded consumer products under the ViPova™, Lexaria Energy Foods, and TurboCBD™ brands. It recently acquired the remaining 49% of its majority owned Poviva Tea LLC subsidiary (http://nnw.fm/Mow3Z). It now owns 100% ownership interest, reaffirming its commitment to the ViPova product lines, as noted by the company in a recent news release.
Separately, in financial news, LXRP has extended the date of its warrants issued on January 19, 2017, to expire on January 19, 2019. The exercise price and the quantity of the warrants has not changed, it said in a 8K SEC filing. LXRP, in its corporate presentation, said that the next round of capital investment is expected to be in “plant to bloodstream” companies, such as itself.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼